Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
Abstract The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia. A single‐center, open‐label study evaluated the PKs of daridorexant in pati...
Enregistré dans:
Auteurs principaux: | Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fc8b4cfe396c4a1ebd06e4c57683c6a4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
par: Norman JL, et autres
Publié: (2016) -
Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function.
par: Anna Jonsson Holmdahl, et autres
Publié: (2021) -
Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
par: Anna Jonsson Holmdahl, et autres
Publié: (2021) -
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
par: Andreas Port, et autres
Publié: (2021) -
Tumor cell apoptosis mediated by the orexins
par: A. S. Diatlova, et autres
Publié: (2021)